1.1 Million Americans Got GLP-1 Prescriptions With No Approved Medical Reason, Records Study Finds

What Happened

A new analysis of U.S. electronic health records has identified roughly 1.1 million adults who were prescribed a GLP-1 medication between 2021 and 2025 without any FDA-approved reason in their chart — no diabetes, no obesity, no qualifying weight-related condition. The study, published in September 2026 in the peer-reviewed journal Obesity, drew on a research dataset covering more than 300 million patient records from health systems using widely deployed medical-record software.

The figure means about 1 in 90 U.S. adults without a labeled indication still received a prescription for liraglutide, semaglutide, or tirzepatide during the study window. Off-label prescribing is legal, but the authors flag a growing population whose risk-benefit profile has never been formally studied — a gap that matters as the drugs expand into new populations.

Who Is Affected

The off-label cohort skews sharply from the average patient population. Among the researchers' findings:

• About one in three of these users had a normal body mass index at the time of prescribing.
• People in this group were six times more likely to have a documented history of eating disorders than comparable non-users — a red flag for misuse of appetite suppression.
• Prescriptions concentrated among women, white patients, privately insured patients, and residents of less socially vulnerable areas, suggesting the expansion beyond labeled indications is accruing disproportionately to more advantaged groups.

The study did not capture compounded or gray-market GLP-1s, so the true population taking these drugs without a medical indication is almost certainly larger than the prescription data alone show.

Timeline

• 2017–2020: GLP-1 receptor agonists are approved for type 2 diabetes and, later, chronic weight management; clinical uptake accelerates.
• 2021–2025: Prescriptions surge nationwide; the records analysis identifies the growing off-label share.
• September 2026: The Obesity journal paper quantifies the population at 1.1 million and calls its risk-benefit profile "uncertain."
• Ongoing: Larger clinical trials are testing GLP-1s for substance-use disorders and other emerging indications that remain off-label today.

What This Means for Researchers

This is a signal about how research compounds escape the clinic. Three takeaways:

• Recorded indication ≠ actual indication. The authors stress that missing chart data can masquerade as off-label use — BMI and comorbidities are underrecorded, and patients who lost weight before entering the dataset may still have qualified. The signal is real but noisier than the headline.
• The benefit side is assumed, not studied. For people without obesity or diabetes, there are no randomized safety data supporting long-term use — the exact inverse of the evidence standard that protects approved populations.
• Surveillance gaps compound. The off-label wave flows in parallel with compounded and unregulated sales channels, meaning adverse events in these users may never reach formal pharmacovigilance systems.

How to Verify Your Peptides

Off-label demand is precisely what fuels the unregulated supply chain. If you source GLP-1-related research compounds, demand analytical proof before anything else:

• Require third-party certificates of analysis with mass-spectrometry and HPLC purity verification.
• Confirm batch-level testing for endotoxin and microbial contamination.
• Compare the vendor's published test results against independent lab databases.
• See our testing overview for a full guide to lab-verification options.

Safe Alternatives

Sourcing decisions matter more when demand outruns legitimate supply. Our peptide research library covers evidence-grade compounds, and our vetted vendor directory lists suppliers that publish verification data.

Sources

Industry reports. Peer-reviewed records analysis published in the journal Obesity (September 2026); regulatory announcements and peer-reviewed literature on GLP-1 indications.